Deborah J. Andrews - 01 Jul 2026 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Reporting relationship: Director
Issuer ticker: LCTX
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 17:00:23 UTC
Prior SEC filing: 04 Aug 2026
Next SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Alexandra Hernandez, as Attorney-in-Fact

Key filing fact

Deborah J. Andrews filed Form 4 for Lineage Cell Therapeutics, Inc. (LCTX) on 02 Jul 2026.

Key facts

This page summarizes Deborah J. Andrews's Form 4 filing for Lineage Cell Therapeutics, Inc. (LCTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 17:00.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001325697 Primary reporting owner

ANDREWS DEBORAH J

Relationship: Director
Address: C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD
Signature: /s/ Alexandra Hernandez, as Attorney-in-Fact
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +125,000
Change %
Price: $0.000000^*
Shares after: 125,000
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 125,000
Exercise price: $1.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.